Peter Pitts joins Brainstorm Cell (OTCQB: BCLI) board of directors
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Brainstorm Cell Therapeutics Inc. expanded its Board of Directors from seven to eight members and appointed Peter Pitts as a director effective May 25, 2026, to serve until the company’s 2026 Annual Meeting of Stockholders and until his successor is elected and qualified.
Pitts, age 67, brings over 30 years of health care public policy experience, including prior service as Associate Commissioner of the U.S. Food & Drug Administration and President of the Center for Medicine in the Public Interest. Upon appointment, he received an option to purchase up to 150,000 shares of common stock, with half vesting immediately and half on the six-month anniversary of issuance. The Board determined he is independent under applicable SEC rules, and the company plans to enter into a standard director indemnification agreement with him.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Board size after change: 8 directors
Director age: 67 years
Option grant size: 150,000 shares
+3 more
6 metrics
Board size after change
8 directors
Increased from seven to eight directors on May 25, 2026
Director age
67 years
Age of new director Peter Pitts
Option grant size
150,000 shares
Stock options granted to Peter Pitts upon board appointment
Immediate vesting portion
50% of options
Half of the 150,000-share option vested upon issuance
Delayed vesting portion
50% of options
Remaining options vest on the six-month anniversary of issuance
Director term
Until 2026 Annual Meeting
Peter Pitts will serve until the 2026 Annual Meeting of Stockholders
Key Terms
indemnification agreement, independent, Regulation FD Disclosure, Item 404(a) of Regulation S-K
4 terms
indemnification agreement regulatory
"The Company will enter into a standard indemnification agreement with Mr. Pitts, a form of which is filed as Exhibit 10.1"
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
independent regulatory
"The Board determined that Mr. Pitts is “independent” as defined under the applicable SEC rules and regulations and the Company’s corporate governance guidelines"
Regulation FD Disclosure regulatory
"Item 7.01 Regulation FD Disclosure. The Company issued a press release on May 28, 2026, regarding Mr. Pitts’ appointment"
Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.
Item 404(a) of Regulation S-K regulatory
"there are no transactions involving Mr. Pitts ... that would require disclosure under Item 404(a) of Regulation S-K"
FAQ
What board change did Brainstorm Cell Therapeutics (BCLI) announce?
Brainstorm Cell Therapeutics increased its Board of Directors from seven to eight members and appointed Peter Pitts as a new director. He will serve until the 2026 Annual Meeting of Stockholders and until a successor is duly elected and qualified under the company’s governance rules.
Who is Peter Pitts, the new director at Brainstorm Cell Therapeutics (BCLI)?
Peter Pitts is a health care public policy expert with more than 30 years of experience. He has been President of the Center for Medicine in the Public Interest since 2004 and previously served as Associate Commissioner of the U.S. Food & Drug Administration from 2001 through 2003.
What equity compensation did Peter Pitts receive from Brainstorm Cell Therapeutics (BCLI)?
Upon joining the board, Peter Pitts received a stock option to purchase up to 150,000 shares of Brainstorm Cell Therapeutics common stock. Half of the options vested immediately on grant, and the remaining half will vest on the six-month anniversary of the issuance date.
Is the new Brainstorm Cell Therapeutics (BCLI) director considered independent?
The Board of Directors determined that Peter Pitts is independent under applicable SEC rules, regulations, and the company’s corporate governance guidelines. This means he meets regulatory standards intended to ensure objective oversight and is not part of the company’s management team.
Will Peter Pitts join Brainstorm Cell Therapeutics (BCLI) director compensation programs?
Peter Pitts will be eligible to participate in the company’s annual non-employee director compensation program if and when the Board re-establishes that program. The filing indicates this program is not currently active but may be reinstated in the future.